Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
For a full scientific overview of SLU-PP-332, see our research reference page: SLU-PP-332 Overview Bulk orders automatically save 20% on any 10+ vials (BAC excluded) Important Notice: This product is sold strictly for laboratory research purposes only
These activate Takeda G-protein receptor 5 (TGR5), increasing cAMP and Epac-mediated vesicle exocytosis and promoting GLP-1 secretion
Triple-hormone-receptor agonist retatrutide for obesitya phase 2 trial
Only about 20% of employers with 200 or more workers currently cover weight-loss drugs, leaving roughly half of commercially insured patients unable to start or stay on therapy
Some individuals may feel slight tightness or mild irritation at the injection site, which usually resolves quickly
Patents for Merck $MRKs (MRK) cancer drug Keytruda are set to expire in 2028, potentially resulting in more competition and lower prices
